Facebook
Twitter
Telegram
Report an ErrorSpero Therapeutics Balance Sheet 2011-2024 | SPRO
Annual Balance Sheet Spero Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-70.8 M | -102 M | -105 M | -77.4 M | -24.2 M | -34.1 M | -87.3 M | -10.3 M | -5.69 M | - | - | - | - |
Long Term Debt |
3.82 M | 4.96 M | 5.97 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.72 M | 1.69 M | 1.36 M | 947 K | 928 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 7.07 M | 4.87 M | 833 K | 365 K | 493 K | 1.01 M | - | - | - | - |
Total Current Liabilities |
37.2 M | 21.6 M | 18.7 M | 14.3 M | 26.7 M | 12.3 M | 8.16 M | - | - | - | - | - | - |
Total Liabilities |
75.5 M | 48.9 M | 82.8 M | 21.4 M | 31.5 M | 13.2 M | 8.52 M | 7.41 M | 7.43 M | - | - | - | - |
Deferred Revenue |
2.13 M | 4.15 M | 1.86 M | - | - | - | - | - | 512 K | - | - | - | - |
Retained Earnings |
-391 M | -414 M | -367 M | -278 M | -199 M | -139 M | -96.8 M | -45.4 M | -18.1 M | - | - | - | - |
Total Assets |
182 M | 125 M | 171 M | 153 M | 106 M | 129 M | 93.5 M | 13.8 M | 7.18 M | - | - | - | - |
Cash and Cash Equivalents |
76.3 M | 109 M | 113 M | 85.2 M | 29.7 M | 34.1 M | 87.3 M | - | - | - | - | - | - |
Book Value |
107 M | 75.9 M | 88.3 M | 132 M | 74.6 M | 116 M | 85 M | 6.36 M | -257 K | - | - | - | - |
Total Shareholders Equity |
107 M | 75.9 M | 88.3 M | 132 M | 74.6 M | 116 M | 84.6 M | -49.2 M | -18.6 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Spero Therapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
3.52 M | 3.82 M | 4.12 M | 4.41 M | 4.68 M | 4.96 M | 5.22 M | 5.47 M | 5.73 M | 5.97 M | 6.19 M | 6.43 M | 6.66 M | 6.89 M | 6.89 M | 6.89 M | 6.89 M | 4.62 M | 4.62 M | 4.62 M | 4.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
71.5 M | 75.5 M | 53.4 M | 44.1 M | 47.7 M | 48.9 M | 32 M | 27.7 M | 83.4 M | 82.8 M | 32.8 M | 29.3 M | 24.6 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 31.5 M | 31.5 M | 31.5 M | 31.5 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 8.52 M | 8.52 M | 8.52 M | 8.52 M | 7.41 M | 7.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
2.87 M | 2.13 M | 13.9 M | 8.71 M | 11.8 M | 10.4 M | 3.73 M | 2.36 M | 2.09 M | 1.86 M | 1.7 M | 1.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-404 M | -391 M | -442 M | -439 M | -427 M | -414 M | -441 M | -429 M | -400 M | -367 M | -338 M | -316 M | -297 M | -278 M | -278 M | -278 M | -278 M | -199 M | -199 M | -199 M | -199 M | -139 M | -139 M | -139 M | -139 M | -96.8 M | -96.8 M | -96.8 M | -96.8 M | -45.4 M | -45.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
168 M | 182 M | 107 M | 98.9 M | 113 M | 125 M | 64.5 M | 63.6 M | 146 M | 171 M | 145 M | 120 M | 143 M | 153 M | 153 M | 153 M | 153 M | 106 M | 106 M | 106 M | 106 M | 129 M | 129 M | 129 M | 129 M | 93.5 M | 93.5 M | 93.5 M | 93.5 M | 13.8 M | 13.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
82.3 M | 76.3 M | 93.8 M | 77.7 M | 96.3 M | 109 M | 50.4 M | 45.4 M | 72.1 M | 113 M | 113 M | 71.6 M | 77 M | 85.2 M | 85.2 M | 85.2 M | 85.2 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 34.1 M | 34.1 M | 34.1 M | 34.1 M | 87.3 M | 87.3 M | 87.3 M | 87.3 M | 10.3 M | 10.3 M | - | - | 5.69 M | - | - | - | 256 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
96.2 M | 107 M | 53.7 M | 54.8 M | 64.8 M | 75.9 M | 32.5 M | 35.9 M | 62.5 M | 88.3 M | 112 M | 90.3 M | 119 M | 132 M | 132 M | 132 M | 132 M | 74.6 M | 74.6 M | 74.6 M | 74.6 M | 116 M | 116 M | 116 M | 116 M | 85 M | 85 M | 85 M | 85 M | 6.36 M | 6.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
96.2 M | 107 M | 53.7 M | 54.8 M | 64.8 M | 75.9 M | 32.5 M | 35.9 M | 62.5 M | 88.3 M | 112 M | 90.3 M | 119 M | 132 M | 132 M | 132 M | 132 M | 74.6 M | 74.6 M | 74.6 M | 74.6 M | 116 M | 116 M | 116 M | 116 M | 84.6 M | 84.6 M | 84.6 M | 84.6 M | -45.4 M | -45.4 M | - | - | -18.6 M | - | - | - | -6.11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency